CN116987680A - 支链氨基酸转氨酶1的功能获得性突变体及其应用 - Google Patents
支链氨基酸转氨酶1的功能获得性突变体及其应用 Download PDFInfo
- Publication number
- CN116987680A CN116987680A CN202210440974.6A CN202210440974A CN116987680A CN 116987680 A CN116987680 A CN 116987680A CN 202210440974 A CN202210440974 A CN 202210440974A CN 116987680 A CN116987680 A CN 116987680A
- Authority
- CN
- China
- Prior art keywords
- bcat1
- amino acid
- leu
- mutant
- chain amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010088278 Branched-chain-amino-acid transaminase Proteins 0.000 title abstract description 13
- 101000766268 Homo sapiens Branched-chain-amino-acid aminotransferase, cytosolic Proteins 0.000 claims abstract description 208
- 102100026437 Branched-chain-amino-acid aminotransferase, cytosolic Human genes 0.000 claims abstract description 207
- 102220363900 c.182A>C Human genes 0.000 claims abstract description 143
- 239000003112 inhibitor Substances 0.000 claims abstract description 50
- 230000000694 effects Effects 0.000 claims abstract description 48
- 108010021466 Mutant Proteins Proteins 0.000 claims abstract description 23
- 102000008300 Mutant Proteins Human genes 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 21
- 101001043970 Bacillus subtilis (strain 168) Branched-chain-amino-acid transaminase 1 Proteins 0.000 claims abstract description 14
- 230000035772 mutation Effects 0.000 claims description 65
- 239000004480 active ingredient Substances 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 230000014509 gene expression Effects 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 15
- 102000004357 Transferases Human genes 0.000 claims description 13
- 108090000992 Transferases Proteins 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 3
- 101710105312 Branched-chain-amino-acid aminotransferase Proteins 0.000 claims description 2
- 101710097328 Branched-chain-amino-acid aminotransferase, cytosolic Proteins 0.000 claims description 2
- 101710194298 Branched-chain-amino-acid aminotransferase, mitochondrial Proteins 0.000 claims description 2
- 101710158343 Probable branched-chain-amino-acid aminotransferase Proteins 0.000 claims description 2
- 101710199693 Putative branched-chain-amino-acid aminotransferase Proteins 0.000 claims description 2
- AZPBDRUPTRGILK-UHFFFAOYSA-N benzotriazol-1-ium-1-ylidenemethanediamine;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C1=CC=C2N(C(=N)N)N=NC2=C1 AZPBDRUPTRGILK-UHFFFAOYSA-N 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 17
- 102000051554 human BCAT1 Human genes 0.000 abstract description 3
- 230000004913 activation Effects 0.000 abstract description 2
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 52
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 51
- 229960000932 candesartan Drugs 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 46
- 206010028980 Neoplasm Diseases 0.000 description 33
- 150000001875 compounds Chemical class 0.000 description 23
- 230000035899 viability Effects 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 239000002083 C09CA01 - Losartan Substances 0.000 description 14
- 101150016587 bcat-1 gene Proteins 0.000 description 14
- 150000005693 branched-chain amino acids Chemical class 0.000 description 14
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 14
- 229960004773 losartan Drugs 0.000 description 14
- WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 description 14
- 229960001023 tibolone Drugs 0.000 description 14
- 210000004881 tumor cell Anatomy 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 13
- 208000005718 Stomach Neoplasms Diseases 0.000 description 12
- 206010017758 gastric cancer Diseases 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 201000011549 stomach cancer Diseases 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000012292 cell migration Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- -1 lung Diseases 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 9
- 208000030159 metabolic disease Diseases 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000002018 overexpression Effects 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 238000011161 development Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 150000004715 keto acids Chemical class 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 208000014018 liver neoplasm Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 108090000340 Transaminases Proteins 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000004709 cell invasion Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 102000014898 transaminase activity proteins Human genes 0.000 description 5
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 4
- 241000208140 Acer Species 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 4
- 108010065920 Insulin Lispro Proteins 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 241001123227 Saccharomyces pastorianus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 208000016097 disease of metabolism Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 108010089804 glycyl-threonine Proteins 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009465 prokaryotic expression Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 244000285963 Kluyveromyces fragilis Species 0.000 description 3
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 3
- 241000235058 Komagataella pastoris Species 0.000 description 3
- 208000030162 Maple syrup disease Diseases 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 201000002313 intestinal cancer Diseases 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 208000024393 maple syrup urine disease Diseases 0.000 description 3
- 208000025113 myeloid leukemia Diseases 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IXTPACPAXIOCRG-ACZMJKKPSA-N Ala-Glu-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N IXTPACPAXIOCRG-ACZMJKKPSA-N 0.000 description 2
- LTSBJNNXPBBNDT-HGNGGELXSA-N Ala-His-Gln Chemical compound N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(N)=O)C(=O)O LTSBJNNXPBBNDT-HGNGGELXSA-N 0.000 description 2
- DPNZTBKGAUAZQU-DLOVCJGASA-N Ala-Leu-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N DPNZTBKGAUAZQU-DLOVCJGASA-N 0.000 description 2
- PEIBBAXIKUAYGN-UBHSHLNASA-N Ala-Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 PEIBBAXIKUAYGN-UBHSHLNASA-N 0.000 description 2
- VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- OLDOLPWZEMHNIA-PJODQICGSA-N Arg-Ala-Trp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O OLDOLPWZEMHNIA-PJODQICGSA-N 0.000 description 2
- XTGGTAWGUFXJSV-NAKRPEOUSA-N Arg-Cys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCN=C(N)N)N XTGGTAWGUFXJSV-NAKRPEOUSA-N 0.000 description 2
- YLVGUOGAFAJMKP-JYJNAYRXSA-N Arg-Met-Tyr Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N YLVGUOGAFAJMKP-JYJNAYRXSA-N 0.000 description 2
- KXOPYFNQLVUOAQ-FXQIFTODSA-N Arg-Ser-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KXOPYFNQLVUOAQ-FXQIFTODSA-N 0.000 description 2
- ISVACHFCVRKIDG-SRVKXCTJSA-N Arg-Val-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O ISVACHFCVRKIDG-SRVKXCTJSA-N 0.000 description 2
- DAPLJWATMAXPPZ-CIUDSAMLSA-N Asn-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(N)=O DAPLJWATMAXPPZ-CIUDSAMLSA-N 0.000 description 2
- HCAUEJAQCXVQQM-ACZMJKKPSA-N Asn-Glu-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HCAUEJAQCXVQQM-ACZMJKKPSA-N 0.000 description 2
- JWKDQOORUCYUIW-ZPFDUUQYSA-N Asn-Lys-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JWKDQOORUCYUIW-ZPFDUUQYSA-N 0.000 description 2
- MDDXKBHIMYYJLW-FXQIFTODSA-N Asn-Met-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N MDDXKBHIMYYJLW-FXQIFTODSA-N 0.000 description 2
- SBHUBSDEZQFJHJ-CIUDSAMLSA-N Asp-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O SBHUBSDEZQFJHJ-CIUDSAMLSA-N 0.000 description 2
- RYKWOUUZJFSJOH-FXQIFTODSA-N Asp-Gln-Glu Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N RYKWOUUZJFSJOH-FXQIFTODSA-N 0.000 description 2
- PSLSTUMPZILTAH-BYULHYEWSA-N Asp-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PSLSTUMPZILTAH-BYULHYEWSA-N 0.000 description 2
- LNENWJXDHCFVOF-DCAQKATOSA-N Asp-His-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC(=O)O)N LNENWJXDHCFVOF-DCAQKATOSA-N 0.000 description 2
- RQHLMGCXCZUOGT-ZPFDUUQYSA-N Asp-Leu-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RQHLMGCXCZUOGT-ZPFDUUQYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- LBSKYJOZIIOZIO-DCAQKATOSA-N Cys-Lys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N LBSKYJOZIIOZIO-DCAQKATOSA-N 0.000 description 2
- KVCJEMHFLGVINV-ZLUOBGJFSA-N Cys-Ser-Asn Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(N)=O KVCJEMHFLGVINV-ZLUOBGJFSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 229940124602 FDA-approved drug Drugs 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- AAOBFSKXAVIORT-GUBZILKMSA-N Gln-Asn-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O AAOBFSKXAVIORT-GUBZILKMSA-N 0.000 description 2
- IPHGBVYWRKCGKG-FXQIFTODSA-N Gln-Cys-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O IPHGBVYWRKCGKG-FXQIFTODSA-N 0.000 description 2
- VEYGCDYMOXHJLS-GVXVVHGQSA-N Gln-Val-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VEYGCDYMOXHJLS-GVXVVHGQSA-N 0.000 description 2
- GCYFUZJHAXJKKE-KKUMJFAQSA-N Glu-Arg-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GCYFUZJHAXJKKE-KKUMJFAQSA-N 0.000 description 2
- CKRUHITYRFNUKW-WDSKDSINSA-N Glu-Asn-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O CKRUHITYRFNUKW-WDSKDSINSA-N 0.000 description 2
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 2
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 2
- UHVIQGKBMXEVGN-WDSKDSINSA-N Glu-Gly-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UHVIQGKBMXEVGN-WDSKDSINSA-N 0.000 description 2
- WNRZUESNGGDCJX-JYJNAYRXSA-N Glu-Leu-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O WNRZUESNGGDCJX-JYJNAYRXSA-N 0.000 description 2
- XEKAJTCACGEBOK-KKUMJFAQSA-N Glu-Met-Phe Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N XEKAJTCACGEBOK-KKUMJFAQSA-N 0.000 description 2
- YRMZCZIRHYCNHX-RYUDHWBXSA-N Glu-Phe-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O YRMZCZIRHYCNHX-RYUDHWBXSA-N 0.000 description 2
- BIYNPVYAZOUVFQ-CIUDSAMLSA-N Glu-Pro-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O BIYNPVYAZOUVFQ-CIUDSAMLSA-N 0.000 description 2
- MRWYPDWDZSLWJM-ACZMJKKPSA-N Glu-Ser-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O MRWYPDWDZSLWJM-ACZMJKKPSA-N 0.000 description 2
- HQTDNEZTGZUWSY-XVKPBYJWSA-N Glu-Val-Gly Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)NCC(O)=O HQTDNEZTGZUWSY-XVKPBYJWSA-N 0.000 description 2
- SOYWRINXUSUWEQ-DLOVCJGASA-N Glu-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O SOYWRINXUSUWEQ-DLOVCJGASA-N 0.000 description 2
- OGCIHJPYKVSMTE-YUMQZZPRSA-N Gly-Arg-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O OGCIHJPYKVSMTE-YUMQZZPRSA-N 0.000 description 2
- LURCIJSJAKFCRO-QWRGUYRKSA-N Gly-Asn-Tyr Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LURCIJSJAKFCRO-QWRGUYRKSA-N 0.000 description 2
- MQVNVZUEPUIAFA-WDSKDSINSA-N Gly-Cys-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)CN MQVNVZUEPUIAFA-WDSKDSINSA-N 0.000 description 2
- QCTLGOYODITHPQ-WHFBIAKZSA-N Gly-Cys-Ser Chemical compound [H]NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O QCTLGOYODITHPQ-WHFBIAKZSA-N 0.000 description 2
- FIQQRCFQXGLOSZ-WDSKDSINSA-N Gly-Glu-Asp Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O FIQQRCFQXGLOSZ-WDSKDSINSA-N 0.000 description 2
- LLZXNUUIBOALNY-QWRGUYRKSA-N Gly-Leu-Lys Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN LLZXNUUIBOALNY-QWRGUYRKSA-N 0.000 description 2
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 2
- POJJAZJHBGXEGM-YUMQZZPRSA-N Gly-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)CN POJJAZJHBGXEGM-YUMQZZPRSA-N 0.000 description 2
- LLWQVJNHMYBLLK-CDMKHQONSA-N Gly-Thr-Phe Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LLWQVJNHMYBLLK-CDMKHQONSA-N 0.000 description 2
- DNVDEMWIYLVIQU-RCOVLWMOSA-N Gly-Val-Asp Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O DNVDEMWIYLVIQU-RCOVLWMOSA-N 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- NNBWMLHQXBTIIT-HVTMNAMFSA-N His-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N NNBWMLHQXBTIIT-HVTMNAMFSA-N 0.000 description 2
- DMHGKBGOUAJRHU-UHFFFAOYSA-N Ile-Arg-Pro Natural products CCC(C)C(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O DMHGKBGOUAJRHU-UHFFFAOYSA-N 0.000 description 2
- LJKDGRWXYUTRSH-YVNDNENWSA-N Ile-Gln-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N LJKDGRWXYUTRSH-YVNDNENWSA-N 0.000 description 2
- HTDRTKMNJRRYOJ-SIUGBPQLSA-N Ile-Gln-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HTDRTKMNJRRYOJ-SIUGBPQLSA-N 0.000 description 2
- DFFTXLCCDFYRKD-MBLNEYKQSA-N Ile-Gly-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N DFFTXLCCDFYRKD-MBLNEYKQSA-N 0.000 description 2
- PMMMQRVUMVURGJ-XUXIUFHCSA-N Ile-Leu-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O PMMMQRVUMVURGJ-XUXIUFHCSA-N 0.000 description 2
- GVKKVHNRTUFCCE-BJDJZHNGSA-N Ile-Leu-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)O)N GVKKVHNRTUFCCE-BJDJZHNGSA-N 0.000 description 2
- PWUMCBLVWPCKNO-MGHWNKPDSA-N Ile-Leu-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PWUMCBLVWPCKNO-MGHWNKPDSA-N 0.000 description 2
- GLYJPWIRLBAIJH-UHFFFAOYSA-N Ile-Lys-Pro Natural products CCC(C)C(N)C(=O)NC(CCCCN)C(=O)N1CCCC1C(O)=O GLYJPWIRLBAIJH-UHFFFAOYSA-N 0.000 description 2
- 241001138401 Kluyveromyces lactis Species 0.000 description 2
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 2
- XBBKIIGCUMBKCO-JXUBOQSCSA-N Leu-Ala-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XBBKIIGCUMBKCO-JXUBOQSCSA-N 0.000 description 2
- DLCOFDAHNMMQPP-SRVKXCTJSA-N Leu-Asp-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DLCOFDAHNMMQPP-SRVKXCTJSA-N 0.000 description 2
- WMTOVWLLDGQGCV-GUBZILKMSA-N Leu-Glu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N WMTOVWLLDGQGCV-GUBZILKMSA-N 0.000 description 2
- POZULHZYLPGXMR-ONGXEEELSA-N Leu-Gly-Val Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O POZULHZYLPGXMR-ONGXEEELSA-N 0.000 description 2
- WRLPVDVHNWSSCL-MELADBBJSA-N Leu-His-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@@H]2C(=O)O)N WRLPVDVHNWSSCL-MELADBBJSA-N 0.000 description 2
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 2
- ZDBMWELMUCLUPL-QEJZJMRPSA-N Leu-Phe-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 ZDBMWELMUCLUPL-QEJZJMRPSA-N 0.000 description 2
- KQFZKDITNUEVFJ-JYJNAYRXSA-N Leu-Phe-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)CC1=CC=CC=C1 KQFZKDITNUEVFJ-JYJNAYRXSA-N 0.000 description 2
- DRWMRVFCKKXHCH-BZSNNMDCSA-N Leu-Phe-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=CC=C1 DRWMRVFCKKXHCH-BZSNNMDCSA-N 0.000 description 2
- FYPWFNKQVVEELI-ULQDDVLXSA-N Leu-Phe-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 FYPWFNKQVVEELI-ULQDDVLXSA-N 0.000 description 2
- JDBQSGMJBMPNFT-AVGNSLFASA-N Leu-Pro-Val Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O JDBQSGMJBMPNFT-AVGNSLFASA-N 0.000 description 2
- XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 2
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 2
- ICYRCNICGBJLGM-HJGDQZAQSA-N Leu-Thr-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(O)=O ICYRCNICGBJLGM-HJGDQZAQSA-N 0.000 description 2
- URHJPNHRQMQGOZ-RHYQMDGZSA-N Leu-Thr-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O URHJPNHRQMQGOZ-RHYQMDGZSA-N 0.000 description 2
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 2
- 108010028658 Leucine Dehydrogenase Proteins 0.000 description 2
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 2
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 description 2
- IMAKMJCBYCSMHM-AVGNSLFASA-N Lys-Glu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN IMAKMJCBYCSMHM-AVGNSLFASA-N 0.000 description 2
- LCMWVZLBCUVDAZ-IUCAKERBSA-N Lys-Gly-Glu Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CCC([O-])=O LCMWVZLBCUVDAZ-IUCAKERBSA-N 0.000 description 2
- ISHNZELVUVPCHY-ZETCQYMHSA-N Lys-Gly-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O ISHNZELVUVPCHY-ZETCQYMHSA-N 0.000 description 2
- HYSVGEAWTGPMOA-IHRRRGAJSA-N Lys-Pro-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O HYSVGEAWTGPMOA-IHRRRGAJSA-N 0.000 description 2
- LOGFVTREOLYCPF-RHYQMDGZSA-N Lys-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-RHYQMDGZSA-N 0.000 description 2
- VVURYEVJJTXWNE-ULQDDVLXSA-N Lys-Tyr-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O VVURYEVJJTXWNE-ULQDDVLXSA-N 0.000 description 2
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- YYEIFXZOBZVDPH-DCAQKATOSA-N Met-Lys-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O YYEIFXZOBZVDPH-DCAQKATOSA-N 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 2
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 2
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 2
- WBNQDOYYEUMPFS-UHFFFAOYSA-N N-nitrosodiethylamine Chemical compound CCN(CC)N=O WBNQDOYYEUMPFS-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- WGXOKDLDIWSOCV-MELADBBJSA-N Phe-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O WGXOKDLDIWSOCV-MELADBBJSA-N 0.000 description 2
- WIVCOAKLPICYGY-KKUMJFAQSA-N Phe-Asp-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N WIVCOAKLPICYGY-KKUMJFAQSA-N 0.000 description 2
- QPVFUAUFEBPIPT-CDMKHQONSA-N Phe-Gly-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O QPVFUAUFEBPIPT-CDMKHQONSA-N 0.000 description 2
- AMBLXEMWFARNNQ-DCAQKATOSA-N Pro-Asn-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]1CCCN1 AMBLXEMWFARNNQ-DCAQKATOSA-N 0.000 description 2
- YFNOUBWUIIJQHF-LPEHRKFASA-N Pro-Asp-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O YFNOUBWUIIJQHF-LPEHRKFASA-N 0.000 description 2
- BFXZQMWKTYWGCF-PYJNHQTQSA-N Pro-His-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BFXZQMWKTYWGCF-PYJNHQTQSA-N 0.000 description 2
- RMODQFBNDDENCP-IHRRRGAJSA-N Pro-Lys-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O RMODQFBNDDENCP-IHRRRGAJSA-N 0.000 description 2
- CGSOWZUPLOKYOR-AVGNSLFASA-N Pro-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 CGSOWZUPLOKYOR-AVGNSLFASA-N 0.000 description 2
- GXWRTSIVLSQACD-RCWTZXSCSA-N Pro-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@@H]1CCCN1)O GXWRTSIVLSQACD-RCWTZXSCSA-N 0.000 description 2
- JDJMFMVVJHLWDP-UNQGMJICSA-N Pro-Thr-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JDJMFMVVJHLWDP-UNQGMJICSA-N 0.000 description 2
- UCTIUWKCVNGEFH-OBJOEFQTSA-N Pro-Val-Gly-Pro Chemical compound N([C@@H](C(C)C)C(=O)NCC(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCCN1 UCTIUWKCVNGEFH-OBJOEFQTSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 241000235072 Saccharomyces bayanus Species 0.000 description 2
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 2
- 241000235060 Scheffersomyces stipitis Species 0.000 description 2
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 2
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- YRNBANYVJJBGDI-VZFHVOOUSA-N Thr-Ala-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)O)N)O YRNBANYVJJBGDI-VZFHVOOUSA-N 0.000 description 2
- NIEWSKWFURSECR-FOHZUACHSA-N Thr-Gly-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O NIEWSKWFURSECR-FOHZUACHSA-N 0.000 description 2
- AQAMPXBRJJWPNI-JHEQGTHGSA-N Thr-Gly-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AQAMPXBRJJWPNI-JHEQGTHGSA-N 0.000 description 2
- JRAUIKJSEAKTGD-TUBUOCAGSA-N Thr-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N JRAUIKJSEAKTGD-TUBUOCAGSA-N 0.000 description 2
- ADPHPKGWVDHWML-PPCPHDFISA-N Thr-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N ADPHPKGWVDHWML-PPCPHDFISA-N 0.000 description 2
- PCMDGXKXVMBIFP-VEVYYDQMSA-N Thr-Met-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(O)=O PCMDGXKXVMBIFP-VEVYYDQMSA-N 0.000 description 2
- WTMPKZWHRCMMMT-KZVJFYERSA-N Thr-Pro-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WTMPKZWHRCMMMT-KZVJFYERSA-N 0.000 description 2
- NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- BDWDMRSGCXEDMR-WFBYXXMGSA-N Trp-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N BDWDMRSGCXEDMR-WFBYXXMGSA-N 0.000 description 2
- OBAMASZCXDIXSS-SZMVWBNQSA-N Trp-Glu-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N OBAMASZCXDIXSS-SZMVWBNQSA-N 0.000 description 2
- DZIKVMCFXIIETR-JSGCOSHPSA-N Trp-Gly-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O DZIKVMCFXIIETR-JSGCOSHPSA-N 0.000 description 2
- MEZCXKYMMQJRDE-PMVMPFDFSA-N Trp-Leu-Tyr Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)CC(C)C)C(O)=O)C1=CC=C(O)C=C1 MEZCXKYMMQJRDE-PMVMPFDFSA-N 0.000 description 2
- WBZOZLNLXVBCNW-LTHWPDAASA-N Trp-Thr-Ile Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)[C@@H](C)O)=CNC2=C1 WBZOZLNLXVBCNW-LTHWPDAASA-N 0.000 description 2
- PALLCTDPFINNMM-JQHSSLGASA-N Trp-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N PALLCTDPFINNMM-JQHSSLGASA-N 0.000 description 2
- DXYWRYQRKPIGGU-BPNCWPANSA-N Tyr-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DXYWRYQRKPIGGU-BPNCWPANSA-N 0.000 description 2
- PJWCWGXAVIVXQC-STECZYCISA-N Tyr-Ile-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PJWCWGXAVIVXQC-STECZYCISA-N 0.000 description 2
- NVZVJIUDICCMHZ-BZSNNMDCSA-N Tyr-Phe-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O NVZVJIUDICCMHZ-BZSNNMDCSA-N 0.000 description 2
- LUMQYLVYUIRHHU-YJRXYDGGSA-N Tyr-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LUMQYLVYUIRHHU-YJRXYDGGSA-N 0.000 description 2
- KUXCBJFJURINGF-PXDAIIFMSA-N Tyr-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=C(C=C3)O)N KUXCBJFJURINGF-PXDAIIFMSA-N 0.000 description 2
- 108010064997 VPY tripeptide Proteins 0.000 description 2
- VDPRBUOZLIFUIM-GUBZILKMSA-N Val-Arg-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N VDPRBUOZLIFUIM-GUBZILKMSA-N 0.000 description 2
- CGGVNFJRZJUVAE-BYULHYEWSA-N Val-Asp-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CGGVNFJRZJUVAE-BYULHYEWSA-N 0.000 description 2
- DLYOEFGPYTZVSP-AEJSXWLSSA-N Val-Cys-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N DLYOEFGPYTZVSP-AEJSXWLSSA-N 0.000 description 2
- ZRSZTKTVPNSUNA-IHRRRGAJSA-N Val-Lys-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(O)=O ZRSZTKTVPNSUNA-IHRRRGAJSA-N 0.000 description 2
- YKNOJPJWNVHORX-UNQGMJICSA-N Val-Phe-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YKNOJPJWNVHORX-UNQGMJICSA-N 0.000 description 2
- LTTQCQRTSHJPPL-ZKWXMUAHSA-N Val-Ser-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N LTTQCQRTSHJPPL-ZKWXMUAHSA-N 0.000 description 2
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 2
- MNSSBIHFEUUXNW-RCWTZXSCSA-N Val-Thr-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N MNSSBIHFEUUXNW-RCWTZXSCSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 108010044940 alanylglutamine Proteins 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 2
- 108010068380 arginylarginine Proteins 0.000 description 2
- 108010077245 asparaginyl-proline Proteins 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 2
- 108010008237 glutamyl-valyl-glycine Proteins 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 108010077515 glycylproline Proteins 0.000 description 2
- 108010084389 glycyltryptophan Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 108010030617 leucyl-phenylalanyl-valine Proteins 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 108010003700 lysyl aspartic acid Proteins 0.000 description 2
- 108010009298 lysylglutamic acid Proteins 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 108010056582 methionylglutamic acid Proteins 0.000 description 2
- 108010005942 methionylglycine Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 108010012581 phenylalanylglutamate Proteins 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical group CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 108010051110 tyrosyl-lysine Proteins 0.000 description 2
- 108010073969 valyllysine Proteins 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 102100035315 2-oxoisovalerate dehydrogenase subunit beta, mitochondrial Human genes 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- MRXZVZVKYZELRU-UHFFFAOYSA-N Ala-Trp-Ser-Ser Chemical compound C1=CC=C2C(CC(NC(=O)C(N)C)C(=O)NC(CO)C(=O)NC(CO)C(O)=O)=CNC2=C1 MRXZVZVKYZELRU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000001967 Branched-chain aminotransferases Human genes 0.000 description 1
- 108050009223 Branched-chain aminotransferases Proteins 0.000 description 1
- 102100026413 Branched-chain-amino-acid aminotransferase, mitochondrial Human genes 0.000 description 1
- 101710142286 Branched-chain-amino-acid transaminase 1 Proteins 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- 101100058144 Caenorhabditis elegans bcat-1 gene Proteins 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010018378 Glomerulonephritis rapidly progressive Diseases 0.000 description 1
- DXMOIVCNJIJQSC-QEJZJMRPSA-N Glu-Trp-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)N DXMOIVCNJIJQSC-QEJZJMRPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101000766294 Homo sapiens Branched-chain-amino-acid aminotransferase, mitochondrial Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000588771 Morganella <proteobacterium> Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical group [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 108010053823 Rho Guanine Nucleotide Exchange Factors Proteins 0.000 description 1
- 102100021708 Rho guanine nucleotide exchange factor 1 Human genes 0.000 description 1
- 102100027610 Rho-related GTP-binding protein RhoC Human genes 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 235000018368 Saccharomyces fragilis Nutrition 0.000 description 1
- 241001466077 Salina Species 0.000 description 1
- 241000192263 Scheffersomyces shehatae Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 102100035115 Testin Human genes 0.000 description 1
- 101710070533 Testin Proteins 0.000 description 1
- 241001313536 Thermothelomyces thermophila Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229960004349 candesartan cilexetil Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 201000005637 crescentic glomerulonephritis Diseases 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940031154 kluyveromyces marxianus Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 108091006026 monomeric small GTPases Proteins 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000013152 negative regulation of cell migration Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229910001453 nickel ion Inorganic materials 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108010073531 rhoC GTP-Binding Protein Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y206/00—Transferases transferring nitrogenous groups (2.6)
- C12Y206/01—Transaminases (2.6.1)
- C12Y206/01042—Branched-chain-amino-acid transaminase (2.6.1.42)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
Abstract
本发明提供了支链氨基酸转氨酶1(BCAT1)的活化功能获得性突变体及其应用。具体地,本发明提供了一种人BCAT1E61A功能获得性活化突变体蛋白(即BCAT1E61A突变蛋白)以及针对所述突变蛋白的靶向抑制剂。与野生型蛋白相比,本发明的靶向抑制剂不仅对突变蛋白有更为显著的抑制作用,而且有效抑制浓度(IC50)显著低于现有BCAT1抑制剂,作用靶点的特异性更强。
Description
技术领域
本发明涉及医药技术领域,涉及支链氨基酸转氨酶1(BCAT1)的功能获得性突变体及其应用,更具体地涉及和BCAT1及BCAT1E61A突变抑制剂在制备预防和/或治疗BCAT1及其BCAT1E61A突变介导的相关代谢疾病药物中的用途。
背景技术
亮氨酸、异亮氨酸和缬氨酸是人体必需氨基酸,它们被统称为支链氨基酸(BCAA)。研究发现支链氨基酸代谢异常通常会导致枫糖尿病(maple syrup urine disease)以及多种癌症(包括胰腺癌、肺癌、胶质瘤以及多种白血病)等疾病。限制或者低支链氨基酸的饮食能缓解这类相关代谢疾病。
支链氨基酸转氨酶(BCAT)是催化支链氨基酸分解代谢第一步的关键酶,主要有两种亚型,一个是定位于细胞胞浆中的BCAT1,另一个是定位于线粒体中的BCAT2。
支链氨基酸转氨酶为PLP依赖的可逆反应,主要作用是将支链氨基酸上的氨基转给α-酮戊二酸(α-KG),产生对应的支链酮酸(BCKA)和谷氨酸。其碳骨架BCKA在BCKA脱氢酶复合体(BCKDH)进一步分解会生成乙酰辅酶A(Ac-CoA)和琥珀酰辅酶A(Suc-CoA),从而进入柠檬酸循环。
研究表明,BCAT或者BCKDH突变或造成枫糖尿病,从而严重影响人体健康。然而,目前对于BCAT蛋白的研究尚不够深入,仅发现了一些BCAT在癌症发生发展过程中存在过表达,未报道过导致BCAT1功能活化的突变形式。
因此,本发明迫切需要进一步BCAT1的各种不同的突变形式,并相应地提供靶向这些不同突变形式的靶向治疗药物。
发明内容
本发明目的就是提供一种新的功能获得性突变形式即BCAT1E61A突变蛋白及其靶向治疗药物。
在本发明第一方面,提供了一种支链氨基酸转移酶1(BCAT1)突变蛋白,所述的突变蛋白在对应于人支链氨基酸转移酶1的第61位存在E→A的突变,并且具有支链氨基酸转移酶活性。
在另一优选例中,所述突变蛋白为功能获得性突变蛋白。
在另一优选例中,所述突变蛋白的转氨酶活性A1与野生型BCAT1蛋白的转氨酶活性A0之比(A1/A0)为约1.5,更佳地为约1.47。
在另一优选例中,所述的人支链氨基酸转移酶1的氨基酸序列如SEQ ID No:1所示。
在另一优选例中,所述的支链氨基酸选自下组:亮氨酸、异亮氨酸、缬氨酸、或其组合。
在另一优选例中,所述突变蛋白的氨基酸序列如SEQ ID No:2所示。
本发明第二方面,提供了一种分离的多核苷酸,所述多核苷酸编码本发明第一方面所述的BCAT1E61A突变蛋白。
本发明第三方面,提供了一种载体,所述载体含有本发明第二方面所述的多核苷酸。
在另一优选例中,所述载体为表达载体。
本发明第四方面,提供了一种宿主细胞,所述宿主细胞含有本发明第三方面所述的载体,或所述宿主细胞的核酸中含有本发明第二方面所述的分离的多核苷酸。
在另一优选例中,所述的宿主细胞包括原核细胞或真核细胞。
在另一优选例中,所述宿主细胞包括来源于以下微生物的细胞:
酿酒酵母(Saccharomyces cerevisiae)、毕赤酵母(Pichia pastoris)、摩纳酵母(Saccharomyces monacensis)、贝酵母(Saccharomyces bayanus)、巴氏酵母(Saccharomyces pastorianus)、卡氏酵母(Saccharomyces carlsbergensis)、粟酒裂殖酵母(Saccharomyces pombe)、马克斯克鲁维酵母(Kluyveromyces marxiamus)、乳酸克鲁维酵母(Kluyveromyces lactis)、脆壁克鲁维酵母(Kluyveromyces fragilis),树干毕赤酵母(Pichia stipites)、休哈塔假丝酵母(Candida shehatae)、热带假丝酵母(Candidatropicalis)、大肠杆菌(Escherichia coli)。
在另一优选例中,所述宿主细胞包括酿酒酵母、毕赤酵母或嗜热毁丝霉。
在另一优选例中,所述宿主细胞表达BCAT1E61A突变蛋白。
本发明第五方面,提供了一种制备本发明第一方面所述的BCAT1E61A突变蛋白的方法,包括步骤:
在适合表达的条件下,培养本发明第四方面所述的宿主细胞,从而表达本发明第一方面所述的BCAT1E61A突变蛋白;和
分离表达产物,从而获得本发明第一方面所述的BCAT1E61A突变蛋白
本发明第六方面,提供了一种本发明第一方面所述的突变蛋白的靶向抑制剂的用途,用于制备一药物组合物或制剂,所述药物组合物或制剂用于治疗BCAT1E61A突变相关的疾病。
在另一优选例中,所述的BCAT1E61A突变相关的疾病选自下组:代谢疾病、癌症或其组合。
在另一优选例中,所述的代谢疾病选自下组:胰岛素抵抗、高胆固醇血症、糖尿病、枫糖尿病、类风湿性关节炎,新月体性肾小球肾炎、或其组合。
在另一优选例中,所述的癌症选自下组:胰腺癌、肺癌、胶质瘤、白血病、肠癌、胃癌、或其组合。
在另一优选例中,所述疾病是BCAT1E61A阳性的疾病。
在另一优选例中,所述抑制剂选自下组:小分子、抗体、多肽、寡核苷酸、适体、或其组合。
在另一优选例中,所述的靶向抑制剂选自下组:坎地沙坦、氯沙坦、替勃龙或其组合。
在另一优选例中,所述药物组合物用于抑制肿瘤的生长、抑制肿瘤的转移、或其组合。
本发明第七方面,提供了一种试剂盒,所述的试剂盒包括:
(a)第一活性成分或含有所述第一活性成分的第一药物组合物,所述第一活性成分为针对本发明第一方面所述的突变蛋白的靶向抑制剂;和
(b)检测试剂,所述检测试剂用于检测支链氨基酸转移酶1(BCAT1)是否存在E61A突变。
在另一优选例中,所述的检测试剂选自下组:引物(PCR正向引物TGCATCATCTTACCCCATCTG(SEQ ID No:3),反向引物:CCAGCTGTCCTTTCTATTTGCT(SEQ ID No:4);退火温度54度,734bp)。
在另一优选例中,所述的试剂盒还含有:
(c)第二活性成分或含有所述第二活性成分的第二药物组合物,所述的第二活性成分用于降低RhoC的表达和/或活性。
在另一优选例中,所述的第二活性成分包括:小分子化合物、抗体、核酸分子、或其组合。
在另一优选例中,所述的第二活性成分选自下组:shRNA、干扰RNA、siRNA、microRNA、或其组合。
在另一优选例中,所述的试剂盒还含有:
(d)第三活性成分或含有所述第三活性成分的第三药物组合物,所述的第三活性成分用于降低BCAT1的表达。
在另一优选例中,所述的第三活性成分包括:小分子化合物、抗体、核酸分子、或其组合。
在另一优选例中,所述的第三活性成分选自下组:shRNA、干扰RNA、siRNA、microRNA、或其组合。
在另一优选例中,所述的试剂盒含有所述的第二活性成分和第三活性成分。
本发明第八方面,提供了一种BCAT1靶向抑制剂的用途,用于制备一药物组合物或制剂,所述药物组合物或制剂用于抑制RhoC的活性。
在另一优选例中,所述的BCAT1靶向抑制剂包括抑制野生型BCAT1的靶向抑制剂、抑制突变型BCAT1的靶向抑制剂、或其组合。
在另一优选例中,所述的突变型BCAT1为BCAT1E61A突变蛋白。
在另一优选例中,所述的BCAT1靶向抑制剂选自下组:坎地沙坦、氯沙坦、替勃龙、抗BCAT1的抗体或其组合。
本发明第九方面,提供了一种活性成分的组合,所述组合包括:
(i)第一活性成分或含有所述第一活性成分的药物组合物,所述第一活性成分为针对本发明第一方面所述的突变蛋白的靶向抑制剂;和
(ii)第二活性成分,所述的第二活性成分用于降低RhoC的表达和/或活性。
本发明第十方面,提供了一种本发明第九方面所述的活性成分的组合的用途,用于制备一药物,所述药物用于治疗BCAT1高表达或突变型BCAT1相关的疾病。
在另一优选例中,所述的疾病选自下组:代谢疾病、癌症或其组合。
在另一优选例中,所述的代谢疾病选胰岛素抵抗、高胆固醇血症、糖尿病、枫糖尿病、或其组合。
在另一优选例中,所述的癌症选自下组:胰腺癌、肺癌、胶质瘤、白血病、肠癌、或其组合。
在另一优选例中,所述的突变型BCAT1为BCAT1E61A突变蛋白。
本发明第十一方面,提供了一种体外抑制RhoC活性的方法,包括步骤:
(a)在BCAT1靶向抑制剂存在下,培养表达BCAT1蛋白和RhoC蛋白的细胞,从而抑制所述所述细胞中的RhoC活性。
在另一优选例中,所述细胞选自下组:肿瘤细胞。
在另一优选例中,所述细胞选自下组:肿瘤细胞TE1、肿瘤细胞MGC803。
在另一优选例中,所述方法是非治疗和非诊断的。
在另一优选例中,所述的BCAT1靶向抑制剂选自下组:坎地沙坦、氯沙坦、替勃龙、抗BCAT1的抗体或其组合。
本发明第十二方面,提供了一种筛选候选治疗药物的方法,包括步骤:
(a)在测试组中,在测试物存在下,测试BCAT1E61A突变蛋白的活性T1;并且在空白对照组中,在测试物不存在下,测试BCAT1E61A突变蛋白的活性T0;其中,除了测试物之外,所述测试组和空白对照组的其他测试条件相同;
(b)将测试组的活性T1与空白对照组的活性T0进行比较;
其中,如果所述的T1显著低于T0,则提示所述测试物为潜在的候选治疗药物。
在另一优选例中,所述的“显著低于”指T1/T0≤0.5,较佳地≤0.25,更佳地≤0.1。
在另一优选例中,所述的BCAT1E61A突变蛋白具有SEQ ID No:2所示的氨基酸序列。
在另一优选例中,所述方法还包括:
(c)测试所述的潜在的候选治疗药物对肿瘤细胞的抑制作用。
在另一优选例中,所述抑制作用包括:对肿瘤细胞生长的抑制、对肿瘤细胞迁移的抑制、或其组合。
在另一优选例中,所述方法还包括:在阳性对照组中,在阳性化合物存在下,测试BCAT1E61A突变蛋白的活性T2;其中,除了阳性化合物之外,所述阳性对照组的其他测试条件与测试组相同;
并将测试组的活性T1与阳性对照组的T2进行比较。
在另一优选例中,所述方法是非治疗和非诊断的。
在另一优选例中,所述的阳性化合物选自下组:坎地沙坦、氯沙坦、替勃龙、抗BCAT1的抗体或其组合。
本发明第十三方面,提供了一种治疗疾病的方法,包括步骤:向需要治疗的受试者施用治疗有效量的BCAT1E61A靶向抑制剂。
在另一优选例中,所述的BCAT1E61A突变相关的疾病选自下组:代谢疾病、癌症或其组合。
在另一优选例中,所述的代谢疾病选自下组:胰岛素抵抗、枫糖尿病、高胆固醇血症、糖尿病、或其组合。
在另一优选例中,所述的癌症选自下组:白血病、胃癌、胶质瘤、肠癌、肺癌、胰腺癌、或其组合。
在另一优选例中,所述疾病是BCAT1E61A阳性的疾病。
在另一优选例中,所述的靶向抑制剂选自下组:坎地沙坦、氯沙坦、替勃龙或其组合。
本发明第十四方面,提供了一种BCAT1E61A突变检测试剂的用途,用于制备以试剂盒,所述试剂盒用于检测患者样本是否存在BCAT1E61A突变。
在另一优选例中,所述试剂盒用于判断患者是否患有BCAT1E61A突变相关的疾病。
在另一优选例中,所述试剂盒含有检测试剂,所述检测试剂用于检测支链氨基酸转移酶1(BCAT1)是否存在E61A突变。
应理解,在本发明范围内中,本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合,从而构成新的或优选的技术方案。限于篇幅,在此不再一一累述。
附图说明
图1显示了BCAT1高表达及BCAT1E61A突变在许多癌症中发生。
图2显示了BCAT1E61A突变促进酶活性。
图3显示了BCAT1高表达及BCAT1E61A突变促进细胞生长。
图4显示了BCAT1高表达及BCAT1E61A突变促进细胞迁移和侵袭。
图5显示了BCAT1及BCAT1E61A突变通过RhoC影响细胞迁移和侵袭。
图6显示了BCAT1E61A突变导致肺组织增生及促进体内支链氨基酸分解代谢。
图7显示了BCAT1E61A突变促进肝癌发生和发展。
图8显示了BCAT1E61A突变促进粒细胞白血病发生。
图9显示了BCAT1分解代谢产物支链酮酸结合RhoC促进RhoC活力。
图10显示了BCAT1高表达及BCAT1E61A突变作用机制模型图。
图11显示了坎地沙坦直接结合BCAT1及BCAT1E61A突变酶活位点抑制酶活。
图12显示了坎地沙坦对BCAT1下游关键因子RhoC活力及细胞迁移的抑制。
图13显示了回补BCAT1分解代谢产物支链酮酸有效挽救坎地沙坦处理细胞对RhoC活力的抑制。
图14显示了靶向BCAT1-RhoC代谢信号轴抑制胃癌细胞体内转移。
图15显示了对BCAT1E61A抑制剂的筛选结果。
具体实施方式
本发明人通过广泛而深入的研究,首次意外地发现了BCAT1E61A功能获得性活化突变体蛋白,即BCAT1E61A突变蛋白。研究表明,本发明的BCAT1E61A突变蛋白在突变后,其催化活性显著提高。本发明还开发针对本发明突变蛋白的靶向抑制剂,并验证了这些靶向抑制剂可用于治疗肿瘤等BCAT1E61A突变相关疾病。在此基础上完成了本发明。
具体地,本发明的实验证明,抑制BCAT1E61A突变,能明显缓解BCAT1E61A突变造成的肿瘤等代谢相关疾病。坎地沙坦等BCAT1特异性靶向抑制剂,可直接结合BCAT1E61A并抑制其活性。坎地沙坦等BCAT1特异性靶向抑制剂可以抑制BCAT1E61A突变造成的肿瘤等疾病。
术语
为了更容易理解本发明,以下具体定义了某些技术和科学术语。除非在本文中另有明确定义,本文使用的所有其它技术和科学术语都具有本发明所属领域的一般技术人员通常理解的含义。在描述本发明之前,应当理解本发明不限于所述的具体方法和实验条件,因为这类方法和条件可以变动。还应当理解本文所用的术语其目的仅在于描述具体实施方案,并且意图不是限制性的,本发明的范围将仅由所附的权利要求书限制。
除非另外定义,否则本文中所用的全部技术与科学术语均具有如本发明所属领域的普通技术人员通常理解的相同含义。如本文所用,在提到具体列举的数值中使用时,术语“约”意指该值可以从列举的值变动不多于1%。例如,如本文所用,表述“约100”包括99和101和之间的全部值(例如,99.1、99.2、99.3、99.4等)。
如本文所用,术语“任选”或“任选地”意味着随后所描述的事件或情况可以发生但不是必须发生、可以有但不是必须有,可以是1个、2个或3个。
缩写
RhoC表示Ras Homolog Family Member C,中文名为Ras同源家族成员C,属于小G蛋白超家族的亚家族成员之一,作为一个分子开关,可以打开或关闭各种细胞内信号通路,还参与许多生理病理过程。
BCAT1及功能获得性活化突变体
支链转氨酶1(branched-chain aminotransferase 1,BCAT1)催化人类支链氨基酸降解的第一步可逆反应,催化支链氨基酸和酮戊二酸通过转氨基反应生成对应的支链酮酸和谷氨酸。
如本文所用,术语“本发明的突变蛋白”、“本发明蛋白”、“本发明的功能获得性活化突变体”、“本发明的功能获得性活化突变蛋白”、或“本发明BCAT1E61A蛋白”可互换使用,指在对应于人支链氨基酸转移酶1的第61位存在E→A的突变并且具有支链氨基酸转移酶活性。应理解,该术语不仅包括在野生型的人BCAT1的氨基酸序列(SEQ ID No:1)基础上具有E61A突变的突变蛋白,还包括可含有额外突变的突变蛋白,只要这些额外突变不影响或基本上不影响BCAT1E61A的转氨酶功能。
如本文所用,术语“E61A”指在氨基酸序列的第61位上具有从谷氨酸(E)突变为亮氨酸(A)的氨基酸突变。相应地,对应的核苷酸密码子GCG突变为GAG。
本发明所涉及的氨基酸序列如下所示:
野生型BCAT1蛋白的氨基酸序列(SEQ ID No:1):
MKDCSNGCSAECTGEGGSKEVVGTFKAKDLIVTPATILKEKPDPNNLVFGTVFTDHMLTVEWSSEFGWEKPHIKPLQNLSLHPGSSALHYAVELFEGLKAFRGVDNKIRLFQPNLNMDRMYRSAVRATLPVFDKEELLECIQQLVKLDQEWVPYSTSASLYIRPTFIGTEPSLGVKKPTKALLFVLLSPVGPYFSSGTFNPVSLWANPKYVRAWKGGTGDCKMGGNYGSSLFAQCEAVDNGCQQVLWLYGEDHQITEVGTMNLFLYWINEDGEEELATPPLDGIILPGVTRRCILDLAHQWGEFKVSERYLTMDDLTTALEGNRVREMFGSGTACVVCPVSDILYKGETIHIPTMENGPKLASRILSKLTDIQYGREESDWTIVLS。
BCAT1E61A突变蛋白的氨基酸序列(SEQ ID No:2):
MKDCSNGCSAECTGEGGSKEVVGTFKAKDLIVTPATILKEKPDPNNLVFGTVFTDHMLTVAWSSEFGWEKPHIKPLQNLSLHPGSSALHYAVELFEGLKAFRGVDNKIRLFQPNLNMDRMYRSAVRATLPVFDKEELLECIQQLVKLDQEWVPYSTSASLYIRPTFIGTEPSLGVKKPTKALLFVLLSPVGPYFSSGTFNPVSLWANPKYVRAWKGGTGDCKMGGNYGSSLFAQCEAVDNGCQQVLWLYGEDHQITEVGTMNLFLYWINEDGEEELATPPLDGIILPGVTRRCILDLAHQWGEFKVSERYLTMDDLTTALEGNRVREMFGSGTACVVCPVSDILYKGETIHIPTMENGPKLASRILSKLTDIQYGREESDWTIVLS。
在本发明中,本发明的突变蛋白还包括其保守性变异体,指与本发明突变蛋白的氨基酸序列(SEQ ID No:2)相比,在除了第61位(E61A)之外的其他位置,有至多10个,较佳地至多8个,更佳地至多5个,最佳地至多3个氨基酸被性质相似或相近的氨基酸所替换而形成多肽。这些保守性变异多肽最好根据表1进行氨基酸替换而产生。
表1
活性成分
本发明还提供了针对本发明突变蛋白的靶向抑制剂及其应用。本发明的突变蛋白的靶向抑制剂可用于抑制BCAT1E61A突变蛋白酶活功能,进而治疗BCAT1E61A突变相关的疾病。
在本发明中,可将本发明突变蛋白的靶向抑制剂作为活性成分用于制备药物,以治疗相关疾病。
在本发明中,所述靶向抑制剂包括(但并不限于):小分子、抗体、多肽、寡核苷酸、适体、ADC、或其组合。
本发明的代表性的靶向抑制剂选自下组:坎地沙坦、氯沙坦、替勃龙或其组合。
坎地沙坦(Candesartan)是一种非肽类血管紧张素Ⅱ受体拮抗剂,可选择性的、难以逆转地阻滞ATI受体,而无明显副作用。主要用于治疗高血压。坎地沙坦结构式如式(I)所示:
氯沙坦(Losartan)结构式如式(II)所示:
利维爱/替勃龙片(Tibolone)如式(III)所示:
药物组合物
由于本发明靶向抑制剂(也称为本发明化合物)具有优异的BCAT1E61A突变蛋白的抑制活性,因此本发明靶向抑制剂(包括化合物及其各种晶型,药学上可接受的盐)以及含有本发明靶向抑制剂为主要活性成分的药物组合物可用于预防和/或治疗(稳定、减轻或治愈)BCAT1E61A突变蛋白相关的疾病。
本发明的药物组合物包含安全有效量范围内的本发明靶向抑制剂及药学上可以接受的赋形剂或载体。其中“安全有效量”指的是:化合物的量足以明显改善病情,而不至于产生严重的副作用。通常,药物组合物含有1-2000mg本发明靶向抑制剂/剂,更佳地,含有10-200mg本发明靶向抑制剂/剂。较佳地,所述的“一剂”为一个胶囊或药片。
本发明的药物组合物包含安全有效量范围内的本发明靶向抑制剂及药学上可以接受的赋形剂或载体。其中“安全有效量”指的是:化合物的量足以明显改善病情,而不至于产生严重的副作用。通常,药物组合物含有1-2000mg本发明靶向抑制剂/剂,更佳地,含有10-200mg本发明靶向抑制剂/剂。较佳地,所述的“一剂”为一个胶囊或药片。
“药学上可接受的载体”指的是:一种或多种相容性固体或液体填料或凝胶物质,它们适合于人使用,而且必须有足够的纯度和足够低的毒性。“相容性”在此指的是组合物中各组份能和本发明靶向抑制剂以及它们之间相互掺和,而不明显降低化合物的药效。药学上可以接受的载体部分例子有纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素钠、纤维素乙酸酯等)、明胶、滑石、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、花生油、橄榄油等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化剂 润湿剂(如十二烷基硫酸钠)、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、无热原水等。
本发明靶向抑制剂或药物组合物的施用方式没有特别限制,代表性的施用方式包括(但并不限于):口服、肠胃外(静脉内、肌肉内或皮下)。
用于口服给药的固体剂型包括胶囊剂、片剂、丸剂、散剂和颗粒剂。在这些固体剂型中,活性化合物与至少一种常规惰性赋形剂(或载体)混合,如柠檬酸钠或磷酸二钙,或与下述成分混合:(a)填料或增容剂,例如,淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸;(b)粘合剂,例如,羟甲基纤维素、藻酸盐、明胶、聚乙烯基吡咯烷酮、蔗糖和阿拉伯胶;(c)保湿剂,例如,甘油;(d)崩解剂,例如,琼脂、碳酸钙、马铃薯淀粉或木薯淀粉、藻酸、某些复合硅酸盐、和碳酸钠;(e)缓溶剂,例如石蜡;(f)吸收加速剂,例如,季胺化合物;(g)润湿剂,例如鲸蜡醇和单硬脂酸甘油酯;(h)吸附剂,例如,高岭土;和(i)润滑剂,例如,滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、十二烷基硫酸钠,或其混合物。胶囊剂、片剂和丸剂中,剂型也可包含缓冲剂。
固体剂型如片剂、糖丸、胶囊剂、丸剂和颗粒剂可采用包衣和壳材制备,如肠衣和其它本领域公知的材料。它们可包含不透明剂,并且,这种组合物中活性化合物或化合物的释放可以延迟的方式在消化道内的某一部分中释放。可采用的包埋组分的实例是聚合物质和蜡类物质。必要时,活性化合物也可与上述赋形剂中的一种或多种形成微胶囊形式。
用于口服给药的液体剂型包括药学上可接受的乳液、溶液、悬浮液、糖浆或酊剂。除了活性化合物外,液体剂型可包含本领域中常规采用的惰性稀释剂,如水或其它溶剂,增溶剂和乳化剂,例知,乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1,3-丁二醇、二甲基甲酰胺以及油,特别是棉籽油、花生油、玉米胚油、橄榄油、蓖麻油和芝麻油或这些物质的混合物等。
除了这些惰性稀释剂外,组合物也可包含助剂,如润湿剂、乳化剂和悬浮剂、甜味剂、矫味剂和香料。
除了活性化合物外,悬浮液可包含悬浮剂,例如,乙氧基化异十八烷醇、聚氧乙烯山梨醇和脱水山梨醇酯、微晶纤维素、甲醇铝和琼脂或这些物质的混合物等。
用于肠胃外注射的组合物可包含生理上可接受的无菌含水或无水溶液、分散液、悬浮液或乳液,和用于重新溶解成无菌的可注射溶液或分散液的无菌粉末。适宜的含水和非水载体、稀释剂、溶剂或赋形剂包括水、乙醇、多元醇及其适宜的混合物。
本发明靶向抑制剂可以单独给药,或者与其他药学上可接受的化合物联合给药。
联合给药时,所述药物组合物还包括与一种或多种(2种,3种,4种,或更多种)其他药学上可接受的化合物。该其他药学上可接受的化合物中的一种或多种可与本发明的化合物同时、分开或顺序地施用。
使用药物组合物时,是将安全有效量的本发明靶向抑制剂适用于需要治疗的哺乳动物(如人),其中施用时剂量为药学上认为的有效给药剂量,对于60kg体重的人而言,日给药剂量通常为1~2000mg,优选20~500mg。当然,具体剂量还应考虑给药途径、病人健康状况等因素,这些都是熟练医师技能范围之内的。
检测用途和试剂盒
本发明还提供用于检测支链氨基酸转移酶1(BCAT1)是否存在E61A突变的检测试剂和检测试剂盒。
本发明的检测试剂或试剂盒可用于检测患者样本是否存在BCAT1E61A突变。优选地,本发明的检测试剂为核酸检测试剂。
本发明的试剂盒用于判断患者是否患有BCAT1E61A突变相关的疾病。
在本发明中,所述试剂盒还可包括使用说明书。所述说明书描述了所述试剂盒或检测的用法、与BCAT1E61A突变相关的疾病等内容。
本发明的主要优点包括:
1.重组人BCAT1E61A功能获得性活化突变体蛋白,相较于野生型,其酶活力显著增强。
2.坎地沙坦、氯沙坦、替勃龙为已批准临床用药,相较于全新药物,安全性有更强保证,在临床试验等环节有显著优势。
3.坎地沙坦、氯沙坦、替勃龙,可以强烈结合,并特异性抑制支链氨基酸转氨酶1(BCAT1)及其功能获得性活化突变蛋白。
4.坎地沙坦、氯沙坦、替勃龙,靶向支链氨基酸转氨酶1(BCAT1)及其功能获得性活化突变,在治疗肿瘤和枫糖尿病等代谢性疾病方面,有巨大应用潜力。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件,例如Sambrook等人,分子克隆:实验室手册(New York:Cold Spring HarborLaboratory Press,1989)中所述的条件,或按照制造厂商所建议的条件。除非另外说明,否则百分比和份数是重量百分比和重量份数。
实施例1 BCAT1高表达或者BCAT1E61A突变在数据库及临床肿瘤样本中普遍存在
1.1 BCAT1高表达在数据库的临床肿瘤样本中普遍存在
通过cbioportal(https://www.cbioportal.org/)数据库的结果可以看到,BCAT1在如胃癌、肺癌、胰腺癌和卵巢癌等多种肿瘤中高表达(图1a)。而且,从Protein Atlas数据库中的生存数据可以看到,BCAT1高表达与生存率呈现负相关,即高表达BCAT1提示较差的预后结果(图1b)。
1.2 BCAT1E61A在数据库的临床肿瘤样本中普遍存在
通过CCLE数据库可以看到BCAT1E61A在白血病、胃癌、食管癌、肺癌细胞系中均有检测到(图1c-d)。而且取自临床的106例肿瘤样本中发现了8例在癌组织中发生突变的样本(图1e-f)。以上结果说明BCAT1E61A在肿瘤发生发展过程中普遍存在。
实施例2 BCAT1E61A突变促进其酶活
2.1原核及真核蛋白表达
以293T细胞cDNA为模板,用PCR克隆出带有相应保护碱基和酶切位点的BCAT1的CDS产物。酶切后的PCR产物分别连接于原核表达载体pET28a和真核表达载体pCDH-puro,其中的真核表达载体在加了用于纯化的flag标签。将连接产物转化DH5α克隆菌株,然后鉴定,测序及抽提质粒。同时,相应的需要以质粒为模板进行PCR点突变,然后同样进行转化、鉴定、测序及抽提质粒。
原核表达则将对应pET28a质粒转化至用于原核表达感受态细胞BL21(DE3)。然后取单克隆,小摇10ml,后按1:1000接种在1L LB培养基中进行扩大培养。在OD值约0.6时,转至16℃,加入0.5mM终浓度IPTG诱导表达过夜,次日离心收集细菌,使用纯化缓冲液(20mMTris pH 8.0,150mM NaCl)重悬,250W功率的超声破碎,3秒间隔破碎细菌,超速离心收集上清。将上清经过5ml的镍离子交换柱吸附蛋白,咪唑洗脱,(洗脱缓冲液成分:25mM Tris,150mM NaCl,25mM Imidazole,pH7.5),竞争下洗脱含相似结构的组氨酸标签的目的蛋白。采用GE的AKTA蛋白纯化系统进一步纯化后收集浓缩蛋白。先启动AKTA系统,待有蛋白质经过UV检测到峰值时,收集蛋白。
真核表达则将对应pCDH-puro质粒转染至293T细胞,于48小时后收取细胞。使用含0.5%NP-40的PBS缓冲液裂解,高速离心收集上清,加入flag-beads富集蛋白并过夜,然后离心清洗flag-beads,加入flag肽段洗脱蛋白,收集上清即是纯化好的真核蛋白。
2.2酶活力检测
1μL纯化的原核5mg/ml BCAT1蛋白或者适量的真核蛋白溶于100μL BCAT1酶活反应体系(5μM PLP,50mM(NH4)2SO4,0.05mM NADH,5mM DTT,5mM酮戊二酸,10mM亮氨酸,1U亮氨酸脱氢酶,100mM K2HPO4,pH 7.4),检测340nm的吸光值变化,取直线区间斜率作为统计结果,与不添加BCAT1蛋白及不加亮氨酸脱氢酶的对照组,相对酶活以百分比方式表示(反应机制如图2a所示)。
2.3 BCAT1E61A突变促进其酶活
使用原核表达的BCAT1和BCAT1E61A突变蛋白,进行酶动力实验。此外,为了排除是否真核修饰影响酶活,使用真核表达的BCAT1和BCAT1E61A突变蛋白,进行酶活力实验。
结果表明:原核表达的BCAT1E61A突变显著促进蛋白催化活力(如图2b所示)。同样地,真核表达的BCAT1E61A突变也显著促进蛋白催化活力(如图2c所示)。
2.4突变细胞系代谢水平整体升高
通过基于LC-MS的非靶向代谢组分析BCAT1突变型细胞系(KATO III和TE1)及野生型细胞系(AGS和KYSE180),发现BCAT1突变细胞系对比野生型细胞系的总体代谢水平都发生上调(如图2d-e所示)。
实施例3 BCAT1及BCAT1E61A促进癌症发展的机制研究
3.1 BCAT1及其BCAT1E61A促进细胞生长
在多种肿瘤细胞系中过表达BCAT1及其BCAT1E61A促进细胞生长(如图3a所示)。在多种肿瘤细胞系中敲除BCAT1及其BCAT1E61A降低细胞克隆生成如图3b所示)。
综上说明,BCAT1高表达或者BCAT1E61A突变可促进肿瘤生长。
3.2BCAT1及其BCAT1E61A促进细胞迁移和侵袭
在多种肿瘤细胞系中敲除BCAT1及其BCAT1E61A降低细胞迁移(如图4a所示)。在多种肿瘤细胞系中过表达BCAT1及其BCAT1E61A促进细胞迁移(如图4b所示)。在肿瘤细胞系中敲除BCAT1及其BCAT1E61A导致细胞侵袭变弱(如图4c所示)。在肿瘤细胞系中过表达BCAT1及其BCAT1E61A促进细胞侵袭(如图4d所示)。
综上说明,BCAT1高表达或者BCAT1E61A突变可以促进肿瘤迁移以及侵袭。
3.3 BCAT1及其BCAT1E61A可与细胞迁移关键因子RhoC互作
通过IP-MS鉴定到BCAT1与RhoC直接互作(如图5a所示),通过CoIP验证RhoC与BCAT1互作(如图5b所示)。通过IHC染色分析发现临床样本中BCAT1及其BCAT1E61A均高表达(如图5c-d所示),而且RhoC活力在癌组织中显著升高(如图5e所示)。通过裸鼠腹膜转移模型发现高表达BCAT1及其BCAT1E61A均促进转移(如图5f-g所示)。
综上说明,BCAT1通过增强RhoC活力以促进肿瘤迁移及侵袭。
3.4 BCAT1E61A突变增强肺部细胞增生
通过CRISPR-Cas9技术,构建了敲入型的Bcat1E61A点突变C57小鼠。并对小鼠的病理进行分型研究。
结果表明,与野生型相比,Bcat1E61A点突变小鼠的肺部支气管增生及肺泡细胞增生(如图6a所示),这提示BCAT1E61A点突变可能在炎症和癌症发生过程起到重要的作用。
3.5 BCAT1E61A突变促进其酶活并促进BCAA分解代谢
通过分离培养转基因小鼠的表皮成纤维细胞,同时在低BCAA培养基中添加缬氨酸-13C5或者亮氨酸-13C6,15N1以追踪支链氨基酸的代谢流。
在标记36小时后,发现标记的支链氨基酸显著减少,而标记的支链酮酸显著增加。这说明BCAT1E61A突变促进其酶活,增强BCAA分解代谢(如图6b-d所示)。
3.6 BCAT1E61A突变促进肝癌发生和发展
野生型和Bcat1E61A点突变杂合和纯合小鼠在出生第14天,腹腔注射二乙基亚硝胺(DEN)2mg/kg,并在给药4周后,腹腔注射四氯化碳(CCl4)1mL/kg,每周2次,共9周,进行肝癌造模(如图7a所示)。造模结束记录小鼠外形、脾、肺等重要脏器、体重和进食量、肝脏/体重比和血清白蛋白水平均无明显变化(如图7b-g所示)。但Bcat1E61A点突变杂合和纯合小鼠谷草转氨酶(AST)显著升高(如图7h所示),纯合小鼠谷丙转氨酶(ALT)降低(如图7i所示)。解剖发现Bcat1E61A点突变杂合和纯合小鼠肝脏表面均有肿瘤发生(如图7j所示)。病理切片检查发现野生型小鼠肝组织恶性病变程度低,而Bcat1E61A点突变杂合和纯合小鼠肝组织细胞恶性程度高,细胞增殖标记物Ki67染色阳性高于野生型小鼠(如图7k所示)。统计显示Bcat1E61A点突变杂合和纯合小鼠的肝脏肿瘤发生率、肝脏肿瘤数目和最大瘤直径均显著高于相同造模的野生型小鼠(如图7l-n所示)。
3.7 BCAT1E61A突变促进粒细胞白血病的发生和发展
Bcat1E61A突变引起小鼠死亡,有巨大的脾、淋巴结和肝脏(如图8a-b所示)。脾脏和肝脏通过标记物染色发现MPO+CD34+(如图8c所示);CD3-CD4-CD19-CD20-CD30-CD79a-PAX5-,同时增殖标记物Ki67染色高阳性和Phospho-Histone H3(PH3)水平明显增高(如图8d所示),这些数据表明BCAT1E61A突变促进粒细胞白血病的发生和发展。
3.8 BCAT1及BCAT1E61A通过下游代谢物BCKA促进RhoC活力
通过使用计算机分子模拟,发现BCKA可以直接结合RhoC,而且等温热滴定(ITC)实验验证了该结果(如图9a所示)。在体外鸟感受交换实验也证实了BCKA可以促进RhoC活力(如图9b所示)。
综上所有结果,分析得出一个模型:BCAT1及其BCAT1E61A促进BCKA产生增加区室化浓度以促进RhoC活力,进一步促进肿瘤的迁移和侵袭(如图10所示)。
实施例4 BCAT1抑制剂筛选
4.1通过酶活力筛选BCAT1E61A抑制剂
使用FDA已批准药物库(FDA approved drug library),终浓度为10μM加入上述实施例2.2的检测BCAT1E61A酶活的反应体系内的吸光值变化。每组三个重复,对照组不加抑制剂,作为活力值的100%。
此外,对于筛选出的具有一定抑制活性的化合物,进一步通过ΔOD值随时间的变化曲线来测量化合物的抑制活性。
结果:
如图15a所示,在六百多种化合物中,绝大多数化合物对于BCAT1E61A酶活没有抑制作用,然而,少数几种对BCAT1E61A酶活有一定的抑制作用,包括坎地沙坦、氯沙坦、替勃龙。
如图15b所示,坎地沙坦、氯沙坦和替勃龙对BCAT1E61A酶活有显著的靶向抑制活性。按对BCAT1E61A酶活的抑制作用大小排序如下:坎地沙坦>氯沙坦>替勃龙。
4.2测定坎地沙坦与BCAT1或BCAT1E61A结合实验
通过改变坎地沙坦的浓度,测定坎地沙坦对野生型和突变型BCAT1E61A的抑制活性。
通过改变底物亮氨酸的浓度,从0.1mM到5mM梯度。等热滴定实验使用纯化的BCAT1或BCAT1E61A蛋白和坎地沙坦。
结果:
如图11a-b所示,坎地沙坦能够以浓度依赖的方式抑制BCAT1或BCAT1E61A的酶活。
如图11c中所示,坎地沙坦能够直接结合BCAT1或BCAT1E61A蛋白,并且,坎地沙坦更强烈地结合BCAT1E61A蛋白。
4.3使用计算机分子模拟BCAT1或BCAT1E61A和坎地沙坦的结合
通过BCAT1或BCAT1E61A结构模型和坎地沙坦三维结构进行软件拟合分析。
结果表明,坎地沙坦能够结合在BCAT1或BCAT1E61A蛋白酶活中心,封闭了BCAT1或BCAT1E61A蛋白与正常底物的结合以抑制其活性(如图11d表示坎地沙坦与BCAT1或BCAT1E61A结构的表面图;图11e为表示坎地沙坦与BCAT1E61A结合位点的局部图)。
实施例5坎地沙坦在活体水平抑制BCAT1或BCAT1E61A活性来降低细胞迁移
5.1坎地沙坦在活体水平抑制过表达BCAT1或BCAT1E61A导致的RhoC活力增加
对过表达BCAT1或BCAT1E61A的细胞系计数后进行处理和不处理坎地沙坦(150μM终浓度),在18小时后裂解细胞,分析其RhoC活力水平。
RhoC活力结果表明,未处理坎地沙坦对照组中BCAT1或BCAT1E61A过表达都明显增加RhoC活力,处理坎地沙坦实验组中BCAT1或BCAT1E61A过表达都明显抑制RhoC活力(如图12a所示)。
5.2坎地沙坦在活体水平抑制BCAT1E61A突变导致的RhoC活力增加
对从转基因小鼠中分离的野生型,杂合Bcat1E61A和纯合Bcat1E61A的成纤维细胞计数后进行处理和不处理坎地沙坦(150μM终浓度)。在18小时后裂解细胞,分析其RhoC活力水平。
RhoC活力结果表明,未处理坎地沙坦对照组中杂合Bcat1E61A和纯合Bcat1E61A都明显增加RhoC活力,而处理过坎地沙坦的实验组中杂合Bcat1E61A和纯合Bcat1E61A的RhoC活力都被明显抑制(如图12b所示)。
5.3坎地沙坦以浓度依赖方式抑制RhoC活力
对肿瘤细胞系TE1和MGC803加入50-250μM终浓度坎地沙坦处理细胞。在18小时后裂解细胞,分析其RhoC活力水平。
RhoC活力结果表明,坎地沙坦在细胞水平以浓度依赖方式抑制RhoC活力(如图12c所示)。
5.4坎地沙坦在活体水平以浓度依赖方式抑制细胞迁移
对肿瘤细胞系TE1和MGC803加入50-250μM终浓度坎地沙坦处理细胞,在18小时后计数细胞约10万/小室细胞进行Transwell实验,分析坎地沙坦对细胞迁移能力的影响。
迁移实验结果表明,坎地沙坦在细胞水平以浓度依赖方式抑制细胞迁移(如图12d所示)。
5.5回补BCAT1分解代谢产物支链酮酸有效挽救坎地沙坦处理细胞对RhoC活力的抑制
对肿瘤细胞系TE1和MGC803加入50-250μM终浓度坎地沙坦处理细胞。同时分别加入BCAA和α-KG,或BCKA和Glu。在18小时后裂解细胞,分析其RhoC活力水平。
RhoC活力结果表明,回补BCKA和Glu能明显挽救坎地沙坦对RhoC活力的抑制(如图13所示)。
5.6靶向BCAT1-RhoC代谢信号轴抑制胃癌细胞体内转移
稳定过表达对照空载质粒,BCAT1野生型质粒或BCAT1E61A突变体的胃癌细胞株SGC7901接种于5周龄裸鼠腹膜内。分别以坎地沙坦,1/5含量支链氨基酸的饮食,或在上述稳定细胞株分别敲减RhoC或ARHGEF1接种于裸鼠腹膜内。接种后,观察记录小鼠外形和体重,5周后,各处理组小鼠麻醉处死后检测腹膜成瘤,并计算腹膜肿瘤指数(PCI)。结果显示接种过表达野生型BCAT1和BCAT1E61A突变体的胃癌细胞的小鼠腹水明显(如图14a所示)且均显著促进胃癌细胞在腹腔内的播散转移(如图14b所示)和接种瘤的重量(如图14c所示)。与对照组相比,坎地沙坦,1/5含量支链氨基酸的饮食以及敲减RhoC和显著降低了过表达野生型BCAT1和BCAT1E61A突变体胃癌细胞的PCI,即能显著抑制胃癌细胞在腹腔内的播散转移(如图14b所示)和接种瘤重量(如图14c所示)。此外,接种空载质粒、BCAT1野生型质粒或BCAT1E61A突变体的胃癌细胞株的各组小鼠之间体重无明显差异,各处理组间小鼠体重也无显著差异(如图14d所示)。
以上结果证明,靶向BCAT1-RhoC代谢信号轴抑制胃癌细胞体内转移。
讨论
本发明首次报道了BCAT1E61A在肿瘤发生发展过程中的重要功能,是癌症驱动基因突变。发现肿瘤临床样本中存在BCAT1E61A突变位点,该突变可以显著提升BCAT1的酶活功能,导致代谢物BCKA显著增加,从而促进下游RhoC的活力。
进一步在小鼠模型中,本发明人也验证了BCAT1突变在癌症发生及发展中的关键作用,尤其是该突变可导致白血病,以及促进化学诱导肝癌的发生发展。
此外,本发明对多种不同化合物进行了通过酶活抑制筛选实验,筛选到了坎地沙坦等数个显著靶向抑制BCAT1突变蛋白的酶活的抑制剂,这些靶向抑制剂可用于抑制BCAT1突变型相关的肿瘤。
在本发明提及的所有文献都在本申请中引用作为参考,就如同每一篇文献被单独引用作为参考那样。此外应理解,在阅读了本发明的上述讲授内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
SEQUENCE LISTING
<110> 复旦大学
<120> 支链氨基酸转氨酶1的功能获得性突变体及其应用
<130> P2021-3504
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 386
<212> PRT
<213> 人工序列(Artificial sequence)
<220>
<223> 野生型BCAT1蛋白
<400> 1
Met Lys Asp Cys Ser Asn Gly Cys Ser Ala Glu Cys Thr Gly Glu Gly
1 5 10 15
Gly Ser Lys Glu Val Val Gly Thr Phe Lys Ala Lys Asp Leu Ile Val
20 25 30
Thr Pro Ala Thr Ile Leu Lys Glu Lys Pro Asp Pro Asn Asn Leu Val
35 40 45
Phe Gly Thr Val Phe Thr Asp His Met Leu Thr Val Glu Trp Ser Ser
50 55 60
Glu Phe Gly Trp Glu Lys Pro His Ile Lys Pro Leu Gln Asn Leu Ser
65 70 75 80
Leu His Pro Gly Ser Ser Ala Leu His Tyr Ala Val Glu Leu Phe Glu
85 90 95
Gly Leu Lys Ala Phe Arg Gly Val Asp Asn Lys Ile Arg Leu Phe Gln
100 105 110
Pro Asn Leu Asn Met Asp Arg Met Tyr Arg Ser Ala Val Arg Ala Thr
115 120 125
Leu Pro Val Phe Asp Lys Glu Glu Leu Leu Glu Cys Ile Gln Gln Leu
130 135 140
Val Lys Leu Asp Gln Glu Trp Val Pro Tyr Ser Thr Ser Ala Ser Leu
145 150 155 160
Tyr Ile Arg Pro Thr Phe Ile Gly Thr Glu Pro Ser Leu Gly Val Lys
165 170 175
Lys Pro Thr Lys Ala Leu Leu Phe Val Leu Leu Ser Pro Val Gly Pro
180 185 190
Tyr Phe Ser Ser Gly Thr Phe Asn Pro Val Ser Leu Trp Ala Asn Pro
195 200 205
Lys Tyr Val Arg Ala Trp Lys Gly Gly Thr Gly Asp Cys Lys Met Gly
210 215 220
Gly Asn Tyr Gly Ser Ser Leu Phe Ala Gln Cys Glu Ala Val Asp Asn
225 230 235 240
Gly Cys Gln Gln Val Leu Trp Leu Tyr Gly Glu Asp His Gln Ile Thr
245 250 255
Glu Val Gly Thr Met Asn Leu Phe Leu Tyr Trp Ile Asn Glu Asp Gly
260 265 270
Glu Glu Glu Leu Ala Thr Pro Pro Leu Asp Gly Ile Ile Leu Pro Gly
275 280 285
Val Thr Arg Arg Cys Ile Leu Asp Leu Ala His Gln Trp Gly Glu Phe
290 295 300
Lys Val Ser Glu Arg Tyr Leu Thr Met Asp Asp Leu Thr Thr Ala Leu
305 310 315 320
Glu Gly Asn Arg Val Arg Glu Met Phe Gly Ser Gly Thr Ala Cys Val
325 330 335
Val Cys Pro Val Ser Asp Ile Leu Tyr Lys Gly Glu Thr Ile His Ile
340 345 350
Pro Thr Met Glu Asn Gly Pro Lys Leu Ala Ser Arg Ile Leu Ser Lys
355 360 365
Leu Thr Asp Ile Gln Tyr Gly Arg Glu Glu Ser Asp Trp Thr Ile Val
370 375 380
Leu Ser
385
<210> 2
<211> 386
<212> PRT
<213> 人工序列(Artificial sequence)
<220>
<223> BCAT1(E61A)突变蛋白
<400> 2
Met Lys Asp Cys Ser Asn Gly Cys Ser Ala Glu Cys Thr Gly Glu Gly
1 5 10 15
Gly Ser Lys Glu Val Val Gly Thr Phe Lys Ala Lys Asp Leu Ile Val
20 25 30
Thr Pro Ala Thr Ile Leu Lys Glu Lys Pro Asp Pro Asn Asn Leu Val
35 40 45
Phe Gly Thr Val Phe Thr Asp His Met Leu Thr Val Ala Trp Ser Ser
50 55 60
Glu Phe Gly Trp Glu Lys Pro His Ile Lys Pro Leu Gln Asn Leu Ser
65 70 75 80
Leu His Pro Gly Ser Ser Ala Leu His Tyr Ala Val Glu Leu Phe Glu
85 90 95
Gly Leu Lys Ala Phe Arg Gly Val Asp Asn Lys Ile Arg Leu Phe Gln
100 105 110
Pro Asn Leu Asn Met Asp Arg Met Tyr Arg Ser Ala Val Arg Ala Thr
115 120 125
Leu Pro Val Phe Asp Lys Glu Glu Leu Leu Glu Cys Ile Gln Gln Leu
130 135 140
Val Lys Leu Asp Gln Glu Trp Val Pro Tyr Ser Thr Ser Ala Ser Leu
145 150 155 160
Tyr Ile Arg Pro Thr Phe Ile Gly Thr Glu Pro Ser Leu Gly Val Lys
165 170 175
Lys Pro Thr Lys Ala Leu Leu Phe Val Leu Leu Ser Pro Val Gly Pro
180 185 190
Tyr Phe Ser Ser Gly Thr Phe Asn Pro Val Ser Leu Trp Ala Asn Pro
195 200 205
Lys Tyr Val Arg Ala Trp Lys Gly Gly Thr Gly Asp Cys Lys Met Gly
210 215 220
Gly Asn Tyr Gly Ser Ser Leu Phe Ala Gln Cys Glu Ala Val Asp Asn
225 230 235 240
Gly Cys Gln Gln Val Leu Trp Leu Tyr Gly Glu Asp His Gln Ile Thr
245 250 255
Glu Val Gly Thr Met Asn Leu Phe Leu Tyr Trp Ile Asn Glu Asp Gly
260 265 270
Glu Glu Glu Leu Ala Thr Pro Pro Leu Asp Gly Ile Ile Leu Pro Gly
275 280 285
Val Thr Arg Arg Cys Ile Leu Asp Leu Ala His Gln Trp Gly Glu Phe
290 295 300
Lys Val Ser Glu Arg Tyr Leu Thr Met Asp Asp Leu Thr Thr Ala Leu
305 310 315 320
Glu Gly Asn Arg Val Arg Glu Met Phe Gly Ser Gly Thr Ala Cys Val
325 330 335
Val Cys Pro Val Ser Asp Ile Leu Tyr Lys Gly Glu Thr Ile His Ile
340 345 350
Pro Thr Met Glu Asn Gly Pro Lys Leu Ala Ser Arg Ile Leu Ser Lys
355 360 365
Leu Thr Asp Ile Gln Tyr Gly Arg Glu Glu Ser Asp Trp Thr Ile Val
370 375 380
Leu Ser
385
<210> 3
<211> 21
<212> DNA
<213> 人工序列(Artificial sequence)
<220>
<223> PCR正向引物
<400> 3
tgcatcatct taccccatct g 21
<210> 4
<211> 22
<212> DNA
<213> 人工序列(Artificial sequence)
<220>
<223> PCR反向引物
<400> 4
ccagctgtcc tttctatttg ct 22
Claims (10)
1.一种支链氨基酸转移酶1(BCAT1)突变蛋白,其特征在于,所述的突变蛋白在对应于人支链氨基酸转移酶1的第61位存在E→A的突变,并且具有支链氨基酸转移酶活性。
2.一种分离的多核苷酸,其特征在于,所述多核苷酸编码权利要求1所述的BCAT1E61A突变蛋白。
3.一种载体,其特征在于,所述载体含有权利要求2所述的多核苷酸。
在另一优选例中,所述载体为表达载体。
4.一种宿主细胞,其特征在于,所述宿主细胞含有权利要求3所述的载体,或所述宿主细胞的核酸中含有权利要求2所述的分离的多核苷酸。
5.一种制备权利要求1所述的BCAT1E61A突变蛋白的方法,其特征在于,包括步骤:
在适合表达的条件下,培养权利要求4所述的宿主细胞,从而表达权利要求1所述的BCAT1E61A突变蛋白;和
分离表达产物,从而获得权利要求1所述的BCAT1E61A突变蛋白。
6.一种权利要求1所述的突变蛋白的靶向抑制剂的用途,其特征在于,用于制备一药物组合物或制剂,所述药物组合物或制剂用于治疗BCAT1E61A突变相关的疾病。
7.一种试剂盒,其特征在于,所述的试剂盒包括:
(a)第一活性成分或含有所述第一活性成分的第一药物组合物,所述第一活性成分为针对权利要求1所述的突变蛋白的靶向抑制剂;和
(b)检测试剂,所述检测试剂用于检测支链氨基酸转移酶1(BCAT1)是否存在E61A突变。
8.一种BCAT1靶向抑制剂的用途,其特征在于,用于制备一药物组合物或制剂,所述药物组合物或制剂用于抑制RhoC的活性。
9.一种活性成分的组合,其特征在于,所述组合包括:
(i)第一活性成分或含有所述第一活性成分的药物组合物,所述第一活性成分为针对权利要求1所述的突变蛋白的靶向抑制剂;和
(ii)第二活性成分,所述的第二活性成分用于降低RhoC的表达和/或活性。
10.一种权利要求9所述的活性成分的组合的用途,其特征在于,用于制备一药物,所述药物用于治疗BCAT1高表达或突变型BCAT1相关的疾病。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210440974.6A CN116987680A (zh) | 2022-04-25 | 2022-04-25 | 支链氨基酸转氨酶1的功能获得性突变体及其应用 |
PCT/CN2023/086648 WO2023207545A1 (zh) | 2022-04-25 | 2023-04-06 | 支链氨基酸转氨酶1的功能获得性突变体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210440974.6A CN116987680A (zh) | 2022-04-25 | 2022-04-25 | 支链氨基酸转氨酶1的功能获得性突变体及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116987680A true CN116987680A (zh) | 2023-11-03 |
Family
ID=88517467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210440974.6A Pending CN116987680A (zh) | 2022-04-25 | 2022-04-25 | 支链氨基酸转氨酶1的功能获得性突变体及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116987680A (zh) |
WO (1) | WO2023207545A1 (zh) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA941464B (en) * | 1993-03-05 | 1994-09-27 | Akzo Nv | Use of pregnane derivative |
US8088603B2 (en) * | 2007-01-16 | 2012-01-03 | Phigenix, Inc. | Compositions and methods for diagnosing, treating, and preventing prostate conditions |
EP2569637B1 (en) * | 2010-05-14 | 2015-04-08 | Deutsches Krebsforschungszentrum | Methods for the diagnosis and prognosis of a tumor using bcat1 protein |
EP2481801A1 (en) * | 2011-01-28 | 2012-08-01 | Deutsches Krebsforschungszentrum | Inhibitors of branched-chain-aminotransferase-1 (BCAT1) for the treatment of neoplasia |
-
2022
- 2022-04-25 CN CN202210440974.6A patent/CN116987680A/zh active Pending
-
2023
- 2023-04-06 WO PCT/CN2023/086648 patent/WO2023207545A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023207545A1 (zh) | 2023-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102061353B1 (ko) | 인간 ezh2의 억제제 및 이의 사용 방법 | |
CN100424096C (zh) | 含有hiv转导结构域的生存素突变体及制备方法和应用 | |
CN110420331B (zh) | Alkbh5抑制物在治疗病毒感染性疾病中的应用 | |
AU736937B2 (en) | Method for suppressing multiple drug resistance in cancer cells | |
JP6264685B2 (ja) | マルチキナーゼ阻害剤、抗癌剤、抗転移剤、薬剤耐性抑制剤、疼痛抑制剤及び止痒薬 | |
CA2244733A1 (en) | Method for inhibiting adenylosuccinate synthetase activity in methylthioadenosine phosphorylase deficient cells | |
CN116987680A (zh) | 支链氨基酸转氨酶1的功能获得性突变体及其应用 | |
WO2009109356A1 (en) | Cytostatic compositions | |
CN112203675A (zh) | 用于改善虚弱和衰老的方法 | |
KR102127218B1 (ko) | 뇌 신경 교종 치료용 약물 제조에서의 화합물의 용도 | |
US10300107B2 (en) | Compositions and methods for CaMKII inhibitors and uses thereof | |
CN116057071B (zh) | 重组灵芝免疫调节蛋白新突变体及其应用 | |
WO2006001275A1 (ja) | グリコーゲン合成酵素を直接活性化する化合物をスクリーニングする方法 | |
WO2013010028A2 (en) | COMPOSITIONS AND METHODS FOR IMPROVED CaMKII INHIBITORS AND USES THEREOF | |
CN110404074B (zh) | Ogdh抑制物在治疗病毒感染性疾病中的应用 | |
CN111139299B (zh) | Josd2蛋白在制备治疗恶性肿瘤药物中的应用 | |
KR20180129585A (ko) | Mage-1에 특이적으로 결합하는 압타머 및 이의 용도 | |
He et al. | Berberrubine is a novel and selective IMPDH2 inhibitor that impairs the growth of colorectal cancer | |
EP4101929A1 (en) | Library construction method, cyclic peptide, fxiia binder and ifngr1 binder | |
AU2015233244B2 (en) | STAT5 inhibitors and use of same | |
JP4634302B2 (ja) | テトラヒドロ葉酸合成酵素遺伝子 | |
WO2020155534A1 (zh) | 寡核苷酸分子及其在肿瘤治疗中的应用 | |
WO2024088275A1 (zh) | 一种萘酰胺化合物治疗耐药性肿瘤的用途 | |
TWI328011B (en) | Recombinant super-compound interferon | |
JP5721211B2 (ja) | 糖尿病の治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |